Wellington Management

Archaea Energy, LLC is a developer and producer of renewable natural gas (RNG) based in Belle Vernon, Pennsylvania. Founded in 2018, the company focuses on capturing waste emissions and transforming them into low-carbon fuel, providing a sustainable solution for high-carbon emission processes that are difficult to electrify. Archaea Energy operates an RNG platform that encompasses the development, construction, and maintenance of RNG facilities across the United States. Through its efforts, the company aims to contribute to decarbonization and the transition to cleaner energy sources.

Verve Therapeutics, Inc. is a genetic medicines company focused on innovative treatments for cardiovascular disease through gene editing. Founded in 2018 and based in Cambridge, Massachusetts, with a research facility in Philadelphia, the company aims to shift the management of cardiovascular conditions from chronic treatments to single-course gene editing therapies. Its initial programs concentrate on the PCSK9 and ANGPTL3 genes, which are known to significantly impact blood lipid levels, a major factor in cardiovascular disease. Verve Therapeutics collaborates with partners such as Beam Therapeutics and Verily to enhance its gene editing delivery technologies. The company is staffed by a team of experts in cardiovascular medicine, human genetics, and drug development, positioning itself to address the challenges of cardiovascular health effectively.

Verve Therapeutics, Inc. is a genetic medicines company focused on innovative treatments for cardiovascular disease through gene editing. Founded in 2018 and based in Cambridge, Massachusetts, with a research facility in Philadelphia, the company aims to shift the management of cardiovascular conditions from chronic treatments to single-course gene editing therapies. Its initial programs concentrate on the PCSK9 and ANGPTL3 genes, which are known to significantly impact blood lipid levels, a major factor in cardiovascular disease. Verve Therapeutics collaborates with partners such as Beam Therapeutics and Verily to enhance its gene editing delivery technologies. The company is staffed by a team of experts in cardiovascular medicine, human genetics, and drug development, positioning itself to address the challenges of cardiovascular health effectively.

Uber is a technology company that operates a ridesharing mobile application, connecting riders with partner drivers in over 300 cities globally. Founded in 2009, Uber has transformed urban mobility by making transportation more accessible and efficient. Users can submit trip requests through the app, which then routes these requests to nearby drivers, facilitating transportation arrangements in real time. In addition to its core ridesharing services, Uber is also advancing into the realm of autonomous vehicles through its Uber Advanced Technologies Group, which focuses on developing self-driving technology aimed at providing safe and reliable transportation. Furthermore, Uber Elevate is exploring the future of aerial ridesharing, collaborating with various stakeholders to establish a framework for air travel innovation. Overall, Uber's operations encompass a diverse range of transportation solutions, enhancing the connectivity of cities and their inhabitants.

Spark Therapeutics is a biotechnology company dedicated to developing gene therapy products aimed at treating debilitating genetic diseases. Notable among its offerings is LUXTURNA, which addresses biallelic RPE65 mutation-associated retinal dystrophy. The company's pipeline includes gene therapy candidates for hemophilia, such as SPK-8011 and SPK-8016, as well as SPK-7001 for choroideremia and SPK-9001 for hemophilia B. Spark is also exploring liver-directed therapies, including SPK-3006 for Pompe disease, and has programs targeting neurodegenerative disorders like Huntington's disease and TPP1 deficiency, a form of Batten disease. In addition to its proprietary development efforts, Spark has collaborations with Pfizer for hemophilia B treatments and with Novartis for the commercialization of LUXTURNA outside the United States. Established in 2013 and headquartered in Philadelphia, Pennsylvania, Spark Therapeutics operates as a subsidiary of Roche Holding AG, leveraging a strong foundation in gene therapy innovation and manufacturing capabilities.